Incident CUD diagnosis in patients with overweight/obesity and no prior history of CUD comparison between propensity−score matched cohorts during 8−month follow−up time period

Population	Semaglutide cohort	Non−GLP1R agonist anti−obesity medications cohort	HR (95% CI)
Overall (n = 53,562/cohort)	0.20% (109)	0.41% (217)	0.51 (0.41−0.64)
Women (n = 38,549/cohort)	0.17% (66)	0.34% (130)	0.52 (0.39−0.70)
Men (n = 13,683/cohort)	0.21% (28)	0.60% (82)	0.34 (0.22−0.53)
age <= 45 years (n = 19,646/cohort)	0.29% (57)	0.51% (101)	0.58 (0.42−0.81)
age 46−64 years (n = 24,914/cohort)	0.17% (42)	0.40% (100)	0.43 (0.30−0.61)
age >= 65 years (n = 9,007/cohort)	<0.11% (<10)	0.21% (19)	0.42 (0.19−0.97)
Black (n = 8,451/cohort)	0.21% (18)	0.50% (42)	0.43 (0.25−0.75)
White (n = 36,842/cohort)	0.16% (59)	0.39% (144)	0.42 (0.31−0.56)
Hispanic (n = 3,787/cohort)	<0.26% (<10)	0.53% (20)	0.41 (0.18−0.93)